In this second episode of a three-part series on SGLT-2 inhibitors Drs. John Russell and Neil Skolnik discuss the renal effects of the SGLT-2 inhibitors, as well as the place of the SGLT-2is in the American Diabetes Association Guidelines and address practical issues about SGLT-2 inhibitor use. In episode 1, Drs. Russell and Skolnik discussed an overview of the CVOTs for the SGLT-2 inhibitors and in episode 3 they will focus heart failure outcomes. This special three-part series is supported by independent educational grant from AstraZeneca.
For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health